

Roche Holding AG

Basel

Independent Limited Assurance Report on 2020
non-financial reporting

to the Corporate Governance and Sustainability
Committee



Independent Limited Assurance Report

on the 2020 non-financial reporting to the Corporate Governance and Sustainability Committee of Roche Holding AG, Basel

We have been engaged to perform assurance procedures to provide assurance on the aspects of the 2020 non-financial reporting of Roche Holding AG, Basel and its consolidated subsidiaries ('Roche') included in the Annual Report 2020 ('Report').

Scope and subject matter

Our assurance engagement relates to limited level of assurance focused on the data and information for the year ended 31 December 2020 disclosed in the Report of Roche.

We have not carried out any work on data reported for prior reporting periods and in respect of projections and targets.

The following specified data and information published in the Report is within the scope of our limited assurance engagement:

- the materiality determination process of Roche at Group level according to the requirements of the 'GRI Standards' and as disclosed on page 60 of the Report;
- the design of the sustainability risks and opportunities determination process based on Roche Group level activities, disclosed on page 58 in the paragraph 'Risk management' of the Report;
- the Safety, Security, Health and Environmental protection ('SHE') key figures (including greenhouse gas emissions for scope 1 & 2 and scope 3 resulting from business flights) in the tables and graphs on page 91 and page 94 to 101 of the Report;
- the figures on the Roche Group level in relation to the payments and donations, disclosed on page 106 of the Report; and
- the management of reporting processes with respect to SHE, payments and donations and contributions key figures as well as the related control environment in relation to the data aggregation of these key figures.

Criteria

The management reporting processes with respect to the non-financial reporting and key figures were prepared by Roche based on the policies and procedures as set forth in the following:

- the Roche Group guideline 'Grants donations and sponsorship (GSD) data collection process' disclosed on the website;
- the Roche Group internal non-financial reporting guidelines based on the 'Responsible Care Health, Safety and Environmental Protection reporting guidelines' published by the European Chemical Industry Council CEFIC and the 'GRI Standards' published in October 2016 by the Global Reporting Initiative (GRI);
- the Roche Group internal Corporate Reporting Manual 'Sustainability Reporting Guidance - Economic Performance' issued 30 March 2020;
- the Roche materiality determination process at Group level based on the 'GRI Standards' published in October 2016 by the Global Reporting Initiative (GRI); and

*PricewaterhouseCoopers AG, Birchstrasse 160, Postfach, CH-8050 Zürich, Switzerland
Telefon: +41 58 792 44 00, Telefax: +41 58 792 44 10, www.pwc.ch*

PricewaterhouseCoopers AG is a member of the global PricewaterhouseCoopers network of firms, each of which is a separate and independent legal entity.

- the defined guidelines, by which SHE, payments, donations and contributions key figures, and sustainability risks and opportunities are internally gathered, collated and aggregated.

Inherent limitations

The accuracy and completeness of non-financial indicators are subject to inherent limitations given their nature and methods for determining, calculating and estimating such data. GHG quantification is subject to inherent uncertainty, because of the incomplete scientific knowledge used to determine emissions factors and the values needed to combine emissions of different gases. Our assurance report should therefore be read in connection with Roche's guidelines, definitions and procedures as well as on the above third-party guidelines used to present the selected non-financial reporting performance.

Roche's responsibility

The Roche Corporate Governance and Sustainability Committee is responsible for both the subject matter and the criteria including the selection, preparation and presentation of the selected information in accordance with the criteria. This responsibility includes the design, implementation and maintenance of related internal control relevant to this reporting process that is free from material misstatement, whether due to fraud or error.

Our independence and quality controls

We are independent of Roche Holding AG in accordance with the International Code of Ethics for Professional Accountants (including International Independence Standards) issued by the International Ethics Standards Board for Accountants (IESBA Code). We have fulfilled our other ethical responsibilities in accordance with the IESBA Code.

PricewaterhouseCoopers AG applies International Standard on Quality Control 1 and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Our responsibility

Our responsibility is to perform a limited assurance engagement and to express conclusion on the aspects of the 2020 non-financial reporting of Roche. We planned and performed our procedures in accordance with the International Standard on Assurance Engagements (ISAE 3000) (Revised) 'Assurance engagements other than audits or reviews of historical financial information' and, in respect of greenhouse gas emissions, with the International Standard on Assurance Engagements (ISAE 3410) 'Assurance Engagements on Greenhouse Gas Statements', issued by the International Auditing and Assurance Standards Board. These standards require that we plan and perform our procedures to obtain limited assurance on whether the specified non-financial information prepared, in all material aspects, in accordance with Roche's policies and procedures, as well as the management and reporting processes together with the related control environment in relation to the data aggregation work as designed and form an appropriate basis for reporting and follow GRI Standards for the non-financial performance of Roche in focus.

A limited assurance engagement is substantially less in scope than a reasonable assurance engagement in relation to both the risk assessment procedures, including an understanding of internal control, and the procedures performed in response to the assessed risks. Consequently, the nature, timing and extent of procedures for gathering sufficient appropriate evidence are deliberately limited relative to a reasonable assurance engagement and therefore less assurance is obtained with a limited assurance engagement than for a reasonable assurance engagement. The procedures selected depend on the assurance practitioner's judgement.

Summary of the work performed

Our assurance procedures included, amongst others, the following work:

- *Review of the application of Roche Group guidelines*
Reviewing the application of the Roche Group non-financial reporting and contributions guidelines;
- *Site visits and management inquiry*
Remotely visiting selected sites of Roche's Pharmaceuticals and Diagnostics divisions in the USA, Switzerland, China and Indonesia. The selection was based on quantitative and qualitative criteria;
Interviewing personnel responsible for internal non-financial reporting and data collection at the sites we visited and

at the Roche Group level to determine the understanding and application of Roche's non-financial and contributions guidelines;

- *Assessment of the key figures*
Performing tests on a sample basis of evidence supporting selected SHE, payments and donations and contributions (e.g. Roche accident rate, energy consumption, CO₂-equivalent emissions, water usage and discharge, donations to political parties in Switzerland) concerning completeness, accuracy, adequacy and consistency;
- *Review of documentation and analysis of relevant policies and principles*
Reviewing relevant documentation on a sample basis, including Roche Group non-financial reporting policies, management of reporting structures and documentation;
Reviewing the principles of the Roche materiality process providing the definition for the development of its adherence to GRI's environmental, social and economic reporting requirements addressing the soundness of the identification process, determination of impacted stakeholders, peer and competition review, integration of relevant regulatory requirements, integration of key organisational values and objectives and report prioritisation of material aspects;
Inspecting the integration of the sustainability risks and opportunities in the Group Risk Management Process and its adherence to the internal guidelines;
- *Assessment of the processes and data consolidation*
Reviewing the management and non-financial reporting processes for SHE, payments and donations, and contributions key figures; and
Assessing the aggregation process of data at Roche Group level.

We have not conducted any work on data other than outlined in the subject matter as defined above. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our assurance conclusion.

Limited assurance conclusion

Based on our work performed nothing has come to our attention causing us to believe that, in all material aspects:

- the Roche materiality determination process at Group level as disclosed does not adhere to the principles and guiding factors (e.g. soundness, stakeholder determination, peer review, relevance of regulatory environment, integration of key organisational values and objectives) defined within the 'GRI Standards';
- the design of the sustainability risks and opportunities determination process at Group level as disclosed does not function as designed;
- the selected key figures mentioned in the scope disclosed within the non-financial reporting in the Roche Annual Report 2020 are not stated in accordance with the reporting criteria; and
- The management and reporting processes to collect and aggregate the SHE, payments and donations and contributions key figures as well as the control environment in relation to the data aggregation are not working as designed.

PricewaterhouseCoopers AG

Christophe Bourgoin

Helene Baron

Zurich, 01 February 2021